Two Sigma Investments
ACXP icon

Two Sigma Investments’s Acurx Pharmaceuticals ACXP Stock Holding History

Two Sigma Investments’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-649
Closed -$31.8K – 2995
2024
Q1 		$31.8K Buy
+649
New +$42.2K ﹤0.01% 2907

Other funds holding ACXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

Two Sigma Investments's ACXP Position: Q2 2024 in Review

Two Sigma Investments sold out of Acurx Pharmaceuticals (ACXP) in Q2 2024, closing a stake of 649 shares — an estimated $31.8K sold.

Two Sigma Investments first reported a position in ACXP in Q1 2024 and held it in 1 quarter. The position peaked at $31.8K in Q1 2024. 25 funds tracked by Wall St. Rank hold ACXP as of Q2 2024.

  • Two Sigma Investments reported no remaining Acurx Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Investments sold 649 Acurx Pharmaceuticals shares in Q2 2024, an estimated $31.8K.
  • Two Sigma Investments first reported a position in Acurx Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Two Sigma Investments's Acurx Pharmaceuticals position peaked at $31.8K in Q1 2024.
  • 25 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2024.

Based on Two Sigma Investments's 13F filing for Q2 2024, filed 14 Aug 2024.